Neurocrine presents new data from KINECT-HD2 study of ingrezza

Neurocrine (NBIX) Biosciences presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three years of treatment with once-daily ingrezza capsules in adults with Huntington’s disease. These findings were presented at the 2025 MDS International Congress of Parkinson’s Disease and Movement Disorders in Honolulu. The KINECT-HD2 study included 154 adult participants who received once-daily ingrezza for up to three years, with an ongoing optional extended-maintenance period. Safety and tolerability were assessed through treatment-emergent adverse events, including serious TEAEs and discontinuations from treatment or the study due to a TEAE. Efficacy was evaluated through Week 156 using changes from baseline in the Unified Huntington’s Disease Rating Scale Total Maximal Chorea score and response status on the Clinical Global Impression of Change and Patient Global Impression of Change scores. Efficacy was also evaluated through Week 50 using TMC mean changes from baseline in subgroups categorized by concomitant antipsychotic use. Results from this analysis indicated that long-term ingrezza treatment (at doses of 40 mg, 60 mg or 80 mg) provided early and sustained improvements in chorea severity, and concomitant use of antipsychotic medication had no apparent effect on chorea improvement.